SIASUN(SZ:300024) 智通财经网·2025-12-21 12:56Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) is advancing in the surgical robotics sector, having successfully passed the listing hearing on the Hong Kong Stock Exchange with Morgan Stanley and Guotai Junan Securities as joint sponsors [1][3]. Company Overview - Precision Medical specializes in the design, development, and manufacturing of surgical robots, with a product lineup that includes three models at different stages of research and development, targeting the market potential of surgical robots [3]. - The company's core products include the Precision® Multi-Port Laparoscopic Surgical Robot and the Precision® Single-Port Laparoscopic Surgical Robot, along with the Precision® Bronchoscopy Robot, which is not a core product [3]. Product Details - The Precision® Multi-Port Laparoscopic Surgical Robot is designed for minimally invasive surgeries, utilizing robotic, imaging, and digital technologies across urology, gynecology, general surgery, and thoracic surgery [3]. - The Precision® Single-Port Laparoscopic Surgical Robot facilitates minimally invasive surgeries through a single small incision or natural orifice, applicable in urology, gynecology, and general surgery [3]. Market Position - According to Frost & Sullivan, Precision Medical is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [4]. Financial Performance - For the fiscal years ending June 30, 2023, and June 30, 2024, Precision Medical reported revenues of approximately RMB 48.04 million and RMB 159.99 million, respectively, with net losses of approximately RMB 213 million and RMB 219 million for the same periods [4][6]. - The company anticipates revenues of RMB 30.25 million and RMB 149.38 million for the six months ending June 30, 2024, and 2025, respectively, with corresponding losses of RMB 132.09 million and RMB 89.09 million [4][7].